Clinical trials: Lipemia
Familial Hypercholesterolemia
Ezetimibe (SCH 58235) Taken With Either Atorvastatin or Simvastatin in Participants With Familial Hypercholesterolemia (MK-0653-018)
The primary objective of this study is to evaluate the efficacy and the safety of ezetimibe (SCH 58235) co-administered with either atorvastatin or simvastatin in participants with homozygous familial hypercholesterolemia (FH).
- Trial name
- NCT03884452
- Testing
- Atorvastatin, Simvastatin, Ezetimibe
- Volunteers
- 50 people
- Sponsor
- Organon and Co
Primary Hypercholesterolaemia
ORBITAL: Open-Label Primary Care Study: Rosuvastatin Based Compliance Initiatives Linked To Achievement Of LDL Goals
24 week open label study to compare the treatment either with rosuvastatin or rosuvastatin plus initiatives to improve compliance.
- Trial name
- NCT00396240
- Testing
- Rosuvastatin, Initiatives to improve compliance
- Volunteers
- 1,294 people
- Sponsor
- AstraZeneca
Hypercholesterolemia
Efficacy of a One-a-Day L. Reuteri NCIMB 30242 Probiotic Supplement Capsule
Background: In recent years, probiotics have shown promise in treating a variety of diseases. Previously, the investigators have reported on the clinical efficacy of Lactobacillus reuteri NCIMB 30242 in improving the lipid…
- Trial name
- NCT01630668
- Testing
- One-a-Day L. reuteri NCIMB 30242 supplement capsule
- Where
- Canada
- Volunteers
- 150 people
- Sponsor
- Micropharma Limited
Hypercholesterolemia, Atherosclerosis
Ezetimibe Plus Simvastatin Versus Simvastatin Alone in African-American Subjects With Primary Hypercholesterolemia (P03377)
The purpose of this study is to evaluate whether coadministration of ezetimibe 10 mg/day with simvastatin 20 mg/day for 12 weeks will result in greater reduction of LDL-C, total cholesterol (TC), triglycerides (TG), non HDL-C…
- Trial name
- NCT00650663
- Testing
- Ezetimibe + Simvastatin, Simvastatin
- Volunteers
- 247 people
- Sponsor
- Organon and Co
Hypertension With Hyperlipidemia
Study to Evaluate the Safety and Efficacy of CJ-30060 in Hypertensive Patients With Hyperlipidemia
To evaluate the safety and efficacy of CJ-30060 compared with amlodipine/valsartan combination therapy and valsartan/rosuvastatin combination therapy in hypertensive patients with hyperlipidemia
- Trial name
- NCT03536598
- Testing
- Amlodipine 10 mg + Valsartan 160 mg + Rosuvastatin 20 mg, Amlodipine 10 mg + Valsartan 160 mg, Valsartan 160 mg + Rosuvastatin 20 mg
- Volunteers
- 203 people
- Sponsor
- HK inno.N Corporation
History of Myocardial Infarction, Hypertriglyceridemia
A Prospective Observational Program Using Digital Technology Tools to Enhance Patient Adherence to Omacor Therapy
A prospective observational program using digital technology tools to enhance patient adherence to Omacor therapy
- Trial name
- DIAPAsOn (NCT03415152)
- Testing
- Omacor (Omega-3-acid ethyl esters)
- Where
- 93 sites in Russia
- Volunteers
- 3,000 people
- Sponsor
- Abbott
Healthy Participants
A Phase I Study Comparing the Relative Bioavailability of a Fixed-Dose Combination of Laroprovstat/Rosuvastatin vs Their Single Therapy Products in Healthy Adults
The purpose of this study is to assess how well laroprovstat and rosuvastatin combined in a single tablet to be taken by mouth works compared with laroprovstat and rosuvastatin individual tablets taken by mouth (relative…
- Trial name
- NCT07316608
- Testing
- Laroprovstat Dose X/Rosuvastatin Dose 1 FCDP test formulation 1, Laroprovstat Dose X/Rosuvastatin Dose 2 FCDP test formulation 1, Laroprovstat Dose X/Rosuvastatin Dose 1 FCDP test formulation 2
- Where
- 2 sites in United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Familial Chylomicronemia Syndrome, Lipoprotein Lipase Deficiency
Phase 2 Study of AKCEA-ANGPTL3-LRx (ISIS 703802) in Participants With Familial Chylomicronemia Syndrome (FCS)
This is a single center, open-label study to evaluate the efficacy of AKCEA-ANGPTL3-LRx for reduction of triglyceride (TG) levels in participants with FCS.
- Conditions
- Familial Chylomicronemia Syndrome, Lipoprotein Lipase Deficiency, Hyperlipoproteinemia Type 1
- Trial name
- NCT03360747
- Testing
- AKCEA-ANGPTL3-LRx
- Where
- Canada
- Volunteers
- 3 people
- Sponsor
- Akcea Therapeutics
Hypercholesterolemia
Efficacy and Safety of Lapaquistat Acetate Coadministered With Atorvastatin in Subjects With Hypercholesterolemia
The purpose of this study is to determine the efficacy of lapaquistat acetate, once daily (QD), coadministered with a statin to lower lipid levels in Subjects with Hypercholesterolemia.
- Trial name
- NCT00864643
- Testing
- Lapaquistat acetate and atorvastatin, Atorvastatin
- Volunteers
- 172 people
- Sponsor
- Takeda
Hyperlipidemia
A Study to Determine the Bioequivalence of SCH 900068 Compared to Marketed Products (Protocol No. P07551)
The intent of this study is to demonstrate that single doses of the Final Market Image (FMI) ezetimibe/atorvastatin 10mg/10mg and 10mg/80mg fixed dose combination (FDC) tablets are bioequivalent to the same doses of ezetimibe…
- Trial name
- NCT01236430
- Testing
- Ezetimibe, Ezetimibe/atorvastatin 10mg/10mg FDC, Atorvastatin 10mg
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Organon and Co
Hypercholesterolemia
Long-Term Safety and Tolerability of Ezetimibe (SCH 58235, MK-0653) With Atovastatin (P02154, MK-0653-017)
The purpose of this study is to examine the long-term safety and tolerability of ezetimibe (SCH 58235) 10 mg once daily or placebo in combination with atorvastatin (10 to 80 mg/day) for up to 12 consecutive months in participants…
- Trial name
- NCT03882892
- Testing
- Ezetimibe, Atovastatin
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Organon and Co
Hyperlipidemia, Hypercholesterolemia
A Study to Evaluate an Investigational Drug in Patients With Mixed Hyperlipidemia (0653A-071)(COMPLETED)
The purpose of this study is to assess the cholesterol lowering effects of an investigational drug in patients with mixed hyperlipidemia (high cholesterol and high triglycerides).
- Conditions
- Hyperlipidemia, Hypercholesterolemia, Hypertriglyceridemia
- Trial name
- NCT00093899
- Testing
- ezetimibe (+) simvastatin
- Volunteers
- 611 people
- Sponsor
- Organon and Co
Hypercholesterolemia
A Study to Investigate LDL-cholesterol Lowering With Inclisiran Compared to Bempedoic Acid in Patients With Atherosclerotic Cardiovascular Disease.
This study is a phase IV, open-label, randomized study designed to evaluate the efficacy of Inclisiran vs. bempedoic acid (BPA) in 400 adult subjects (≥ 18 years) at very high and high risk for cardiovascular events as defined by…
- Trial name
- NCT06431763
- Testing
- Inclisiran sodium, BPA
- Where
- 55 sites in Germany
- Volunteers
- 402 people
- Sponsor
- Novartis Pharmaceuticals
Hypercholesterolemia, Dyslipidemia
A Multiple Dose Study of PF-04950615 (RN316) in Subjects on High Doses of Statins
This study will investigate the effect of PF-04950615, a new investigational lipid lowering agent, on LDL-C and other lipids.
- Trial name
- NCT01342211
- Testing
- Statin, PF-04950615 (RN316), Satin
- Where
- 44 sites in United States, Canada
- Volunteers
- 93 people
- Sponsor
- Pfizer
Hypercholesterolemia
Effect of Alirocumab on Lipid Metabolism in Adults With Elevated LDL-Cholesterol
Primary Objective: To assess the effects of subcutaneous (SC) doses of alirocumab on the elimination (measured by Fractional Clearance Rate (FCR)) of apolipoprotein B (apoB) in low density lipoprotein (LDL) in adults with mildly…
- Trial name
- NCT01959971
- Testing
- alirocumab
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Sanofi
Atherosclerotic Cardiovascular Disease
Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease
Study CKJX839B12302 is a pivotal Phase III trial to evaluate the benefits of inclisiran on major adverse cardiovascular (MACE) events in participants with established cardiovascular disease (CVD).
- Trial name
- VICTORION-2P (NCT05030428)
- Testing
- Inclisiran sodium 300 mg
- Where
- 983 sites in United States, Argentina and 48 more
- Volunteers
- 17,004 people
- Sponsor
- Novartis Pharmaceuticals
Hypertriglyceridemia
Diazoxide Choline Controlled-Release Tablet (DCCR) for Very High Triglycerides
The hypothesis of this study is that DCCR is effective as both monotherapy and in combination with a statin in lowering triglycerides in subjects with very high triglycerides
- Trial name
- NCT00973271
- Testing
- 290 mg DCCR, 435 mg DCCR, 135 mg fenofibric acid
- Sponsor
- Essentialis, Inc.
Hypertriglyceridemia, Cardiovascular Disease
[E]PANOVA Combined With a [S]TATIN in [P]ATIENTS With HYPERT[R]IGLYCER[I]DEMIA to Reduce Non-HDL CHOLES[T]EROL
The primary objective is to evaluate the efficacy of adding Epanova (2 g or 4 g daily) to an optimal statin monotherapy for lowering non-high-density lipoprotein (non-HDL) cholesterol in subjects with persistent…
- Trial name
- ESPRIT (NCT01408303)
- Testing
- Olive oil, 4g, omega-3-carboxylic acids, 2g, omega-3-carboxylic acids, 4g
- Where
- 89 sites in United States
- Volunteers
- 646 people
- Sponsor
- AstraZeneca
Overweight and Obesity, NAFLD
Study to Evaluate the Safety and Efficacy of ASC41 in Overweight and Obese Subjects
The primary objective of this study is to evaluate the safety, tolerability and compare the pharmacokinetic parameters of ASC41, a THR beta agonist tables in overweight and obese subjects who have elevated LDL-C .
- Conditions
- Overweight and Obesity, NAFLD, Hyperlipidemia
- Trial name
- NCT04686994
- Testing
- ASC 41
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Gannex Pharma Co., Ltd.
Coronary Disease, Coronary Arteriosclerosis
A Coronary IVUS Study to Compare Torcetrapib/Atorvastatin to Atorvastatin Alone in Subjects With Coronary Heart Disease
The Torcetrapib project was terminated on December 2, 2006 due to safety findings. To look at ultrasound images taken in the blood vessels of the heart and to look at various lipids in the blood of people with known coronary…
- Conditions
- Coronary Disease, Coronary Arteriosclerosis, Hyperlipidemia
- Trial name
- ILLUSTRATE (NCT00134173)
- Testing
- torcetrapib/atorvastatin, atorvastatin
- Where
- 146 sites in United States, Belgium and 4 more
- Volunteers
- 1,100 people
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.